PDCD7

PDCD7 (the U11-associated 59K protein) is a component of the U11/U12 di-snRNP of the minor spliceosome, where it bridges core di-snRNP proteins to support complex assembly and U12-type intron recognition (PMID:16096647, PMID:18347052). It is directly bound by the U11/U12-65K protein through the 65K N-terminal half, an interaction that contributes to di-snRNP formation and intron bridging in the minor prespliceosome (PMID:16096647), and it also contacts the U11-48K protein at the U11/U12 interface, with 48K depletion destabilizing the di-snRNP (PMID:18347052). Beyond its spliceosomal role, PDCD7 has context-specific functions: its murine ortholog ES18 promotes apoptosis in T-cells and is transcriptionally regulated during T-cell death induced by several stimuli (PMID:10037816), and in oral squamous cell carcinoma PDCD7 acts as a tumor suppressor, transactivating E-cadherin through a GC-box in its promoter while being repressed by miR-134, placing it in a miR-134–PDCD7–E-cadherin axis whose loss increases oncogenicity and metastasis (PMID:29971778). How the splicing, apoptotic, and tumor-suppressive activities of PDCD7 relate mechanistically has not been characterized in the available corpus.

1. 1999 Medium

   Established the first cellular function for the PDCD7 ortholog by linking it to programmed cell death, addressing whether the gene had any phenotypic role.

   Evidence Transient overexpression of mouse ES18 in T-cell lymphoma with apoptosis readout and transcript regulation under dexamethasone, staurosporine, and C2-ceramide

   PMID:10037816

   Open questions at the time

   • No binding partner or molecular mechanism for the apoptotic effect identified
   • No placement in a defined apoptotic signaling pathway
   • Relationship to later-defined splicing function unaddressed
2. 2005 High

   Reframed PDCD7/59K as a minor-spliceosome component by demonstrating a direct interaction with the U11/U12-65K protein, answering what molecular complex the protein belongs to.

   Evidence Direct protein-protein binding assays plus in vitro splicing inhibition targeting the 65K binding site on U12 snRNA

   PMID:16096647

   Open questions at the time

   • Region of 59K mediating the interaction not mapped
   • Functional consequence of disrupting the 65K–59K contact specifically not isolated
3. 2008 Medium

   Positioned 59K at the U11/U12 di-snRNP interface by mapping a second direct contact to the U11-48K protein, refining how the protein integrates into the complex.

   Evidence Site-specific RNA-protein cross-linking and RNAi knockdown of 48K with splicing and complex-stability readouts

   PMID:18347052

   Open questions at the time

   • 59K role inferred largely from 48K manipulation rather than direct 59K knockdown
   • Quantitative contribution of 59K to di-snRNP stability not isolated
4. 2018 High

   Defined a tumor-suppressive role by placing PDCD7 in a miR-134–PDCD7–E-cadherin transcriptional axis, answering how PDCD7 loss drives cancer progression.

   Evidence CRISPR knockout in oral squamous cell carcinoma, luciferase reporters with wild-type and mutant 3'UTR, E-cadherin promoter transactivation assay, and in vivo mouse metastasis model

   PMID:29971778

   Open questions at the time

   • Mechanism of promoter transactivation (direct DNA binding vs cofactor recruitment) at the GC-box not resolved
   • Connection between nuclear transactivation activity and spliceosomal role unexplained
   • Generality beyond oral squamous cell carcinoma untested

• How PDCD7's roles in minor-spliceosome assembly, apoptosis, and E-cadherin transactivation are mechanistically unified remains unresolved.
• No structural model of 59K within the U11/U12 di-snRNP
• No demonstration that splicing function underlies the apoptotic or tumor-suppressive phenotypes
• Mode of action in promoter transactivation undefined